Pittsburgh Compound B (11C-PIB) and fluorodeoxyglucose (18F-FDG) PET in Patients with Alzheimer’s Disease Mild Cognitive Impairment and Healthy Controls

摘要

Amyloid load in the brain using ¹¹C-PIB PET and cerebral glucose metabolism using ¹⁸F-FDG PET were evaluated in patients with mild Alzheimer’s disease (AD, n=18), mild cognitive impairment (MCI, n=24) and controls (CTR, n=18). ¹¹C-PIB binding potential (BPND) was higher in prefrontal cortex, cingulate, parietal cortex, and precuneus in AD compared to CTR or MCI, and in prefrontal cortex for MCI compared to CTR. For ¹⁸F-FDG, rCMRGlu was decreased in precuneus and parietal cortex in AD compared to CTR and MCI, with no MCI-CTR differences. For the AD-CTR comparison, precuneus BPND area under the ROC curve (AUC) was 0.938 and parietal cortex rCMRGlu AUC was 0.915; for the combination AUC was 0.989. ¹¹C-PIB PET BPND clearly distinguished diagnostic groups, and combined with ¹⁸F-FDG PET rCMRGlu this effect was stronger. These PET techniques provide complementary information in strongly distinguishing diagnostic groups in cross-sectional comparisons that need testing in longitudinal studies.